Healthcare provider profile · identity verified

Jose Antonio Abrego, MD

Internal Medicine · CHELSEA, MA · NPI 1205808722

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	505	155
Lisinopril	Lisinopril	369	105
Amlodipine Besylate	Amlodipine Besylate	312	96
Omeprazole	Omeprazole	286	82
Albuterol Sulfate Hfa	Albuterol Sulfate	209	51
Metoprolol Succinate	Metoprolol Succinate	201	62
Simvastatin	Simvastatin	200	54
Levothyroxine Sodium	Levothyroxine Sodium	168	46
Gabapentin	Gabapentin	165	49
Tamsulosin Hcl	Tamsulosin Hcl	157	52
Metformin Hcl	Metformin Hcl	155	50
Losartan Potassium	Losartan Potassium	123	37
Rosuvastatin Calcium	Rosuvastatin Calcium	123	50
Pantoprazole Sodium	Pantoprazole Sodium	113	38
Jardiance	Empagliflozin	95	31
Olmesartan Medoxomil	Olmesartan Medoxomil	94	26
Trulicity	Dulaglutide	92	28
Metformin Hcl Er	Metformin Hcl	90	22
Alendronate Sodium	Alendronate Sodium	89	24
Lorazepam	Lorazepam	84	23
Ibuprofen	Ibuprofen	79	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	76	25
Zolpidem Tartrate	Zolpidem Tartrate	72	18
Eliquis	Apixaban	70	18
Sertraline Hcl	Sertraline Hcl	69	21
Trazodone Hcl	Trazodone Hcl	69	23
Hydrochlorothiazide	Hydrochlorothiazide	68	24
Fluticasone Propionate	Fluticasone Propionate	66	28
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	66	suppressed
Ozempic	Semaglutide	65	20
Farxiga	Dapagliflozin Propanediol	64	16
Carvedilol	Carvedilol	61	21
Pregabalin	Pregabalin	61	18
Famotidine	Famotidine	59	23
Furosemide	Furosemide	59	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	58	19
Tramadol Hcl	Tramadol Hcl	57	14
Torsemide	Torsemide	56	16
Allopurinol	Allopurinol	54	18
Valsartan	Valsartan	53	23
Chlorthalidone	Chlorthalidone	51	17
Lidocaine	Lidocaine	50	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	48	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	47	suppressed
Diclofenac Sodium	Diclofenac Sodium	46	20
Finasteride	Finasteride	46	18
Tizanidine Hcl	Tizanidine Hcl	43	18
Fluoxetine Hcl	Fluoxetine Hcl	42	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	42	13
Alprazolam	Alprazolam	40	12
Oxycodone Hcl	Oxycodone Hcl	39	11
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	33	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	33	13
Felodipine Er	Felodipine	32	suppressed
Lovastatin	Lovastatin	32	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	32	16
Oxybutynin Chloride Er	Oxybutynin Chloride	31	suppressed
Diazepam	Diazepam	30	suppressed
Atenolol	Atenolol	29	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	29	suppressed
Glipizide	Glipizide	28	suppressed
Propranolol Hcl Er	Propranolol Hcl	27	suppressed
Ammonium Lactate	Ammonium Lactate	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	26	11
Mounjaro	Tirzepatide	26	suppressed
Prednisone	Prednisone	25	16
Glipizide-Metformin	Glipizide/Metformin Hcl	24	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	24	suppressed
Xarelto	Rivaroxaban	23	suppressed
Clotrimazole	Clotrimazole	22	suppressed
Meclizine Hcl	Meclizine Hcl	22	suppressed
Ventolin Hfa	Albuterol Sulfate	22	12
Mirtazapine	Mirtazapine	21	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Colchicine	Colchicine	20	suppressed
Nabumetone	Nabumetone	20	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	suppressed
Spironolactone	Spironolactone	19	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	18	suppressed
Naproxen	Naproxen	18	12
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Sildenafil Citrate	Sildenafil Citrate	18	suppressed
Warfarin Sodium	Warfarin Sodium	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Clonazepam	Clonazepam	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	13
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	16	suppressed
Symbicort	Budesonide/Formoterol Fumarate	16	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	15	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Nystatin	Nystatin	13	suppressed
Tresiba Flextouch U-100	Insulin Degludec	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error